{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:35:38Z","timestamp":1764714938804,"version":"build-2065373602"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"B.I.R.D. Foundation Europe"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.phrs.2019.104583","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T12:48:01Z","timestamp":1575636481000},"page":"104583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives"],"prefix":"10.1016","volume":"152","author":[{"given":"Rebecca","family":"De Lorenzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Punzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lorioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Rovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Canti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Barera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Rovere-Querini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/humupd\/dmn013","article-title":"Bidirectional effects on autoimmunity and reproduction","volume":"14","author":"Cervera","year":"2008","journal-title":"Hum. Reprod. Update"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0010","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4049\/jimmunol.1601600","article-title":"Antenatal suppression of IL-1 protects against inflammation-induced fetal injury and improves neonatal and developmental outcomes in mice","volume":"198","author":"Nadeau-Vall\u00e9e","year":"2017","journal-title":"J Immunol."},{"key":"10.1016\/j.phrs.2019.104583_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/561494","article-title":"The role of cytokines and inflammatory cells in perinatal brain injury","volume":"2012","author":"McAdams","year":"2012","journal-title":"Neurol. Res. Int."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/aji.12216","article-title":"IL\u20101 receptor blockade prevents fetal cortical brain injury but not preterm birth in a mouse model of inflammation\u2010induced preterm birth and perinatal brain injury","volume":"71","author":"Leitner","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bpobgyn.2015.03.003","article-title":"Autoimmune connective tissue diseases","volume":"29","author":"Ostensen","year":"2015","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104583_bib0030","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3899\/jrheum.140583","article-title":"Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project","volume":"42","author":"Bharti","year":"2015","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/BOR.0000000000000415","article-title":"Pregnancy and reproductive aspects of systemic lupus erythematosus","volume":"29","author":"Andreoli","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/annrheumdis-2017-211641","article-title":"Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study","volume":"77","author":"Skorpen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0045","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/annrheumdis-2018-214790","article-title":"Reproductive health outcomes in women with psoriatic arthritis","volume":"78","author":"Murray","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104583_bib0050","first-page":"1","article-title":"Safety of fertility treatments in women with systemic autoimmune diseases (SADs)","author":"Vanni","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","article-title":"State of the art: reproduction and pregnancy in rheumatic diseases","volume":"14","author":"Ostensen","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"2-3","key":"10.1016\/j.phrs.2019.104583_bib0065","doi-asserted-by":"crossref","first-page":"J266","DOI":"10.1016\/j.jaut.2011.11.016","article-title":"The autoimmune bases of infertility and pregnancy loss","volume":"38","author":"Carp","year":"2012","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.phrs.2019.104583_bib0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.autrev.2016.07.017","article-title":"Pregnancy in patients with autoimmune disease: a reality in 2016","volume":"15","author":"Tincani","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00404-014-3536-6","article-title":"Antiphospholipid syndrome and other autoimmune diseases associated with chronic intervillositis","volume":"291","author":"Revaux","year":"2015","journal-title":"Arch. Gynecol. Obstet."},{"issue":"7","key":"10.1016\/j.phrs.2019.104583_bib0080","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203312441269","article-title":"Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome","volume":"21","author":"Canti","year":"2012","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0085","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/aji.12341","article-title":"Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion","volume":"73","author":"Poulton","year":"2015","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.phrs.2019.104583_bib0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/asheducation-2011.1.9","article-title":"Too much of a good thing at the site of tissue injury: the instructive example of the complement system predisposing to thrombotic microangiopathy","volume":"2011","author":"Liszewski","year":"2011","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/17512433.2017.1305268","article-title":"The use of biologics in pregnant patients with rheumatic disease","volume":"10","author":"Ostensen","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/1744666X.2019.1541739","article-title":"Use of synthetic and biologic DMARDs during pregnancy","volume":"15","author":"Balbi","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0301-2115(98)00252-8","article-title":"Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion","volume":"83","author":"Daher","year":"1999","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0115","first-page":"543","article-title":"Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-alpha and interferon-gamma in preterm labor","volume":"82","author":"Bahar","year":"2003","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijgo.2004.08.020","article-title":"Tumor necrosis factor receptor 1 expression and early spontaneous abortion","volume":"88","author":"Yu XW","year":"2005","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod. Rheumatol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104583_bib0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2174\/1389201019666171226152448","article-title":"Biologics in inflammatory immune-mediated systemic diseases","volume":"18","author":"Moroncini","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/ror.0.0040081","article-title":"Dynamics of immunoglobulins at the feto-maternal interface","volume":"4","author":"Saji","year":"1999","journal-title":"Rev. Reprod."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti\u2013tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint, Bone, Spine: revue du rhumatisme"},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0155","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum","volume":"68","author":"Murashima","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0165","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14656566.2016.1197204","article-title":"Challenges and treatment options for rheumatoid arthritis during pregnancy","volume":"17","author":"Gerosa","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0175","first-page":"823","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Clin. Epidemiol. Res."},{"issue":"40","key":"10.1016\/j.phrs.2019.104583_bib0180","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.phrs.2019.104583_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104340","article-title":"The therapeutic journey of biologic agents: There will be an end?","volume":"147","author":"Atzeni","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104583_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/cei.13359","article-title":"The immunology of the fetal-placental unit comes of age","author":"De Lorenzo","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0195","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/rheumatology\/ker302","article-title":"Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use","volume":"50","author":"Hazes","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0200","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous Anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Broms","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104583_bib0210","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.12936","article-title":"Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease","volume":"40","author":"Deepak","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104583_bib0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod. Toxicol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104583_bib0220","first-page":"1399","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0225","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104583_bib0230","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3899\/jrheum.101316","article-title":"The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population","volume":"38","author":"Crijns","year":"2011","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0235","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2018-213023","article-title":"Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study","volume":"77","author":"Tsao","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104583_bib0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","article-title":"Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-alpha use in females with immune mediated diseases; a systematic review and meta-analysis","volume":"76","author":"Komaki","year":"2017","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0245","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology Oxford (Oxford)"},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0250","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1209","article-title":"Infectious complications with the use of biologic response modifiers in infants and children","volume":"138","author":"Davies","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/myc.12576","article-title":"Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-alpha) inhibitors","volume":"60","author":"Tragiannidis","year":"2017","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0260","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to Anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter european TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023714","article-title":"Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study","volume":"9","author":"Tsao","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"865 PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD Exposed to immunomodulators and biologic therapy","volume":"142","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2019.104583_bib0280","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to Anti-TNF-alpha during pregnancy","volume":"8","author":"Esteve-Sole","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0285","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1542\/peds.2014-0054","article-title":"Anti-TNF-alpha therapy may cause neonatal neutropenia","volume":"134","author":"Guiddir","year":"2014","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.phrs.2019.104583_bib0290","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2015-208442","article-title":"Anti-TNFalpha agents curb platelet activation in patients with rheumatoid arthritis","volume":"75","author":"Manfredi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.MIB.0000440984.86659.4f","article-title":"Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children","volume":"20","author":"Bortlik","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0300","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6791","key":"10.1016\/j.phrs.2019.104583_bib0310","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/bmj.302.6791.1489","article-title":"Persistence of antibody after accelerated immunisation with diphtheria\/tetanus\/pertussis vaccine","volume":"302","author":"Ramsay","year":"1991","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.phrs.2019.104583_bib0315","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.autrev.2016.07.014","article-title":"Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation","volume":"15","author":"Levy","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0320","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.phrs.2019.104583_bib0325","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17512433.2018.1525293","article-title":"The use of biologics and small molecules in pregnant patients with rheumatic diseases","volume":"11","author":"Gerosa","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"year":"2017","series-title":"Fachinformation RoActemra","author":"European Medicines Agency","key":"10.1016\/j.phrs.2019.104583_bib0330"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2019.104583_bib0335","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1297-319X(10)70001-4","article-title":"Tocilizumab: therapy and safety management","volume":"77","author":"Pham","year":"2010","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0340","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/14397595.2016.1147405","article-title":"Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan","volume":"26","author":"Nakajima","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104583_bib0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.reprotox.2016.01.002","article-title":"Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center","volume":"60","author":"Weber-Schoendorfer","year":"2016","journal-title":"Reprod. Toxicol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0350","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3109\/14397595.2016.1140256","article-title":"Tocilizumab and pregnancy: Four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab","volume":"26","author":"Kaneko","year":"2016","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0966-3274(03)00059-5","article-title":"Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys","volume":"12","author":"Schroder","year":"2003","journal-title":"Transpl. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/toxsci\/kfq316","article-title":"Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys","volume":"119","author":"Vaidyanathan","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0365","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phrs.2019.104583_bib0370","first-page":"1426","article-title":"The effects of rituximab treatment during pregnancy on a neonate","volume":"91","author":"Friedrichs","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2019.104583_bib0375","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin. Dev. Immunol."},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104583_bib0380","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation : a consensus report issued by the Austrian societies of gastroenterology and hepatology and rheumatology and rehabilitation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien. Klin. Wochenschr."},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0385","first-page":"3227","article-title":"Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS)","volume":"66","author":"Chang","year":"2014","journal-title":"."},{"key":"10.1016\/j.phrs.2019.104583_bib0390","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key093","article-title":"Five successful pregnancies with antenatal anakinra exposure","author":"Smith","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.phrs.2019.104583_bib0395","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0400","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/bdra.10130","article-title":"Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies","volume":"67","author":"Abe","year":"2003","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104583_bib0405","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/annrheumdis-2018-213004","article-title":"Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy","volume":"77","author":"Bitter","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0410","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0415","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0420","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bjd.17086","article-title":"Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies","volume":"180","author":"Watson","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104583_bib0425","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09546634.2018.1468066","article-title":"Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab","volume":"30","author":"Galluzzo","year":"2019","journal-title":"J. Dermatolog. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0430","first-page":"168","article-title":"A case series of patients with psoriasis exposed to biologic therapy during pregnancy: the BIOBADADERM register and a review of the literature","volume":"108","author":"Echeverria-Garcia","year":"2017","journal-title":"Actas Dermosifiliogr."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0435","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1744666X.2019.1561282","article-title":"From mother to baby: antenatal exposure to monoclonal antibody biologics","volume":"15","author":"Pham-Huy","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104583_bib0440","first-page":"264","article-title":"Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding","volume":"13","author":"Martinez Lopez","year":"2017","journal-title":"Reumatol. Clin."},{"issue":"9","key":"10.1016\/j.phrs.2019.104583_bib0445","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2019.104583_bib0450","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.phrs.2019.104583_bib0455","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/1756-185X.13130","article-title":"2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","volume":"20","author":"Louthrenoo","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104583_bib0460","first-page":"86","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","author":"Group WHOMGRS","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"issue":"4","key":"10.1016\/j.phrs.2019.104583_bib0465","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1191\/096032700678815765","article-title":"Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFa monoclonal antibody","volume":"19","author":"Treacy","year":"2000","journal-title":"Hum. Exp. Toxicol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0470","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1476-5381.2011.01812.x","article-title":"Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets","volume":"166","author":"Martin","year":"2012","journal-title":"Br. J. Pharmacol."},{"year":"2003","series-title":"Kineret, INN-anakinra","author":"Agency EEM","key":"10.1016\/j.phrs.2019.104583_bib0475"},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0480","first-page":"1021","article-title":"Successful outcome of two pregnancies in patients with adult-onset Still\u2019s disease treated with IL-1 receptor antagonist (anakinra)","volume":"29","author":"Fischer-Betz","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104583_bib0485","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","article-title":"Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review","volume":"103","author":"Miyasaka","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104583_bib0490","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.phrs.2019.104583_bib0495","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8648651","article-title":"Common adverse effects of anti-TNF agents on gestation","volume":"2016","author":"Fasoulakis","year":"2016","journal-title":"Obstet. Gynecol. Int."},{"issue":"10","key":"10.1016\/j.phrs.2019.104583_bib0500","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.tins.2012.06.001","article-title":"TNF\u03b1 in synaptic function: switching gears","volume":"35","author":"Santello","year":"2012","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2019.104583_bib0505","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pharmthera.2013.04.013","article-title":"Microglia during development and aging","volume":"139","author":"Harry","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104583_bib0510","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2012.00055","article-title":"The complement system at the embryo implantation site: friend or foe?","volume":"3","author":"Bulla","year":"2012","journal-title":"Front. Immunol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819319103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819319103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:02:38Z","timestamp":1760911358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819319103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":102,"alternative-id":["S1043661819319103"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104583","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104583"}}